1.Peng-Peng Xu#, Di Fu#, Jian-Yong Li#, Jian-Da Hu#, Xin Wang#, Jian-Feng Zhou#, Hao Yu, Xia Zhao, Yao-Hui Huang, Lu Jiang, Feng Liu, Li-Ping Su, Zhuo-Wen Chen, Qing-Shu Zeng, Jie-Ping Chen, Mei-Yun Fang, Jun Ma, Ting Liu, Yong-Ping Song, Kang Yu, Yan Li, Lu-Gui Qiu, Xie-Qun Chen, Jian Gu, Jin-Song Yan, Ming Hou, Heng-Ye Huang, Li Wang, Shu Cheng, Yang Shen, Hui Xiong, Sai-Juan Chen, Wei-Li Zhao. Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial. Lancet Haematology. 2019 Jun;6(6):e328-e337.(IF=30.153)
2.Zhou XX, Chen N, Xu HZ, Zhou XM, Wang JH, Fang XS, Zhang Y, Li Y, Yang J, Wang X*. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma. Journal of Hematology & Oncology, 2020,Jun 16;13(1):77(IF=23.168)
3.Zhou XX, Fang XS, Jiang YJ, Geng LY, Li XY, Li Y, Lu K, Li PP, Lv X, Wang X*. Klotho, an anti-aging gene, acts as a tumor suppressor and inhibitor of IGF-1R signaling in diffuse large B cell lymphoma. Journal of Hematology & Oncology. 2017 Feb 2;10(1):37. (IF=23.168)
4.Liu Y, Zhou X*, Wang X*. Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities. Journal of Hematology & Oncology. 2021;14(1):125. Published 2021 Aug 17.(IF= 23.168)
5.Chu Y, Zhou X*, Wang X*. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress. Journal of Hematology & Oncology. 2021;14(1):88. Published 2021 Jun 5. doi:10.1186/s13045-021-01097-z(IF=23.168)
6.Zheng Tian†, Ming Liu†, Ya Zhang* and Xin Wang*. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. Journal of Hematology & Oncology.2021 May 3;14(1):75. (IF=23.168)
7.Zhang, Y., Wang, X*. Targeting the Wnt/β-catenin signaling pathway in cancer. Journal of Hematology & Oncology. 2020 Dec 4;13(1):165.(IF=23.168)
8.Zhou X*#, Zhan L#, Huang K, Wang X*. The functions and clinical significance of circRNAs in hematological malignancies. Journal of Hematology & Oncology. 2020;13(1):138. 2020 Oct 17(IF=23.168)
9.Ming-Ci Cai#,Shu Cheng#,Xin Wang#,Jian-Da Hu#,Yong-Ping Song#,Yao-Hui Huang,Zi-Xun Yan,Yu-Jie Jiang,Xiao-Sheng Fang,Xiao-Yun Zheng,Li-Hua Dong,Meng-Meng Ji,Li Wang,Peng-Peng Xu,Wei-Li Zhao. CEOP/IVE/GDP Alternating Regimen Compared With CEOP as the First-Line Therapy for Newly Diagnosed Patients With Peripheral T Cell Lymphoma: Results From a Phase 2, Multicenter, Randomized, Controlled Clinical Trial. Genome medicine. 2020 Apr 30;12(1):41. (IF=15.266)
10.Yu Z, Zhou X*,Wang X*. Metabolic reprogramming in hematological malignancies: advances and clinical perspectives [published online ahead of print, 2022 Jun 30]. Cancer Res. 2022;can.22.0917. doi:10.1158/0008-5472.CAN-22-0917(IF=13.312)
11.Yang J, Li Y, Zhang Y, Fang XS, Chen N, Zhou XX*, Wang X*. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling. Journal of Experimental & Clinical Cancer Research, 2020 Jul 25;39(1):142. (IF=12.658)
12.Hu S, Ren S, Cai Y, Liu J, Han Y, Zhao Y, Yang J, Zhou X, Wang X. Glycoprotein PTGDS promotes tumorigenesis of diffuse large B-cell lymphoma by MYH9-mediated regulation of Wnt-β-catenin-STAT3 signaling. Cell Death Differ. 2022 Mar;29(3):642-656. doi: 10.1038/s41418-021-00880-2.(IF= 12.067)
13.Zhao Y, Yang J, Liu JR, Cai YQ, Han Y, Hu SF, Ren S, Zhou XX*, Wang X*. Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma. Cell Death & Disease. 2021 Jun 23;12(7):640. (IF=9.685)
14.Han Y, Hu X, Yun X, Liu J, Yang J, Tian Z, Zhang X, Zhang Y, Wang X. Nucleolar and spindle associated protein 1 enhances chemoresistance through DNA damage repair pathway in chronic lymphocytic leukemia by binding with RAD51. Cell Death & Disease. 2021 Nov 15;12(11):1083. (IF=9.685)
15.Zhang Y, Zhou X, Li Y, Xu Y, Lu K, Li P, Wang X*. Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia. Oncogene. 2018 Oct;37(41):5520-5533. (IF:8.756)
16.Yin Z, Zhang Y, Wang X. Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Biomarker Research. 2021 Jul 13;9(1):58. (IF= 8.633)
17.Cai YQ#, Feng R#. Lu TG, Chen XM, Zhou XX*, Wang X*. Novel insights into the m6A-RNA methyltransferase METTL3 in cancer. Biomarker Research. 2021 Apr 20 , 9(1):27 (IF= 8.633 )
18.Yun X, Zhang Y*, Wang X*. Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia. Biomarker Research. 2020;8:40. 2020 Sep 7(IF=8.633)
19.Zhang X, Han Y, Hu X, Wang H, Tian Z, Zhang Y*, Wang X*. Competing endogenous RNA networks related to prognosis in chronic lymphocytic leukemia: comprehensive analyses and construction of a novel risk score model. Biomark Res. 2022 Oct 21;10(1):75. doi: 10.1186/s40364-022-00423-y.(IF=8.633)
20.Xiaomin Chen,Xiangxiang Zhou*,Xin Wang*. m6A binding protein YTHDF2 in cancer. Experimental hematology & oncology. 2022 Apr 5;11(1):21. (IF=8.593)
21.Nie Y, Yun X, Zhang Y*, Wang X*. Targeting metabolic reprogramming in chronic lymphocytic leukemia. Experimental hematology & oncology. 2022;11(1):39. Published 2022 Jun 27. doi:10.1186/s40164-022-00292-z(IF=8.593)
22.Li Y, Wang X*.The role of cullin4B in human cancers. Experimental hematology & oncology. 2017 Jun 15;6:17.(IF=8.593)
23.Yang J, Wang X*.Role of long non-coding RNAs in lymphoma: A systematic review and clinical perspectives. Critical Review in Oncology /Hematology. 2019 Sep ;141:13-22.(IF=6.625)
24.Yiqing Cai, Lili Feng, Xin Wang*. Targeting the tumor promoting effects of adenosine in chronic lymphocytic leukemia. Critical Review in Oncology /Hematology. 2018 Jun;126:24-31. (IF:6.625)
25.Lu T, Shi L, Shi G, Cai Y, Hu S, Liu J, Ren S, Zhou X*, Wang X*. Derivation and validation of a lipid-covered prognostic model for mature T-cell lymphomas. Cancer Cell International. 2021 Jul 5;21(1):348.(IF= 6.429)
26.Li-li Feng, Yi-qing Cai, Ming-chen Zhu, Li-jie Xing, Xin Wang*.The yin and yang functions of extracellular ATP and adenosine in tumor immunity. Cancer Cell International. 2020 Apr 7;20:110 (IF= 6.429)
27.Shuai Ren, Yiqing Cai, Shunfeng Hu, Jiarui Liu, Yi Zhao, Mengfei Ding, Xiaomin Chen, Linquan Zhan, Xiangxiang Zhou* and Xin Wang*, Berberine exerts anti-tumor activity in diffuse large B-cell lymphoma by modulating c-myc/CD47 axis. Biochemical Pharmacology, 2021 Jun;188:114576. (IF= 6.1)
28.Jiarui Liu, Yang Han, Shunfeng Hu, Yiqing Cai, Juan Yang, Shuai Ren,Yi Zhao, Tiange Lu, Xiangxiang Zhou* and Xin Wang*. Circulating Exosomal MiR-107 Restrains Tumorigenesis in Diffuse Large B-Cell Lymphoma by Targeting 14-3-3η. Frontiers in cell and developmental biology, 2021 Apr 27;9:667800. (IF= 6.081)
29.Tan Sang, Juan Yang, Jiarui Liu, Yang Han, Ying Li, Xiangxiang Zhou *& Xin Wang*. AMOT suppresses tumor progression via regulating DNA damage response signaling in diffuse large B-cell lymphoma. Cancer gene therapy. 2021 Nov;28(10-11):1125-1135.(IF= 5.845)
30.Tian Z, Liu M, Fang X, Zhou X, Li P, Li Y, Zhang L, Liu F, Zhang Y*, Wang X*. Distinct Age-Related Clinical Features and Risk Assessment in Chinese With Chronic Lymphocytic Leukemia. Frontiers in Oncology. 2022 May 12;12:885150. doi: 10.3389/fonc.2022.885150.(IF=5.738)
31.Hu X, Wang H, Yuan D, Qu H, Li Y, Wang N, Wang X, Liu X, Xu H, Zhang Y*, Wang X*. An Extended Prognostic Index of the ISSWM Score Based on Thyroid Complications in Waldenström Macroglobulinemia/Lymphoplasmacytoid Lymphoma. Frontiers in Oncology. 2022 May 13;12:870258.(IF=5.738)
32.Yun X, Sun X, Hu X, Zhang H, Yin Z, Zhang X, Liu M, Zhang Y*, Wang X*.Prognostic and Therapeutic Value of Apolipoprotein A and a New Risk Scoring System Based on Apolipoprotein A and Adenosine Deaminase in Chronic Lymphocytic Leukemia. Frontiers in Oncology. 2021 Jul 1;11:698572.(IF= 5.738)
33.Zhai Y, Yuan D, Ge X, Hu S, Li P, Fang X, Li Y, Zhou X and Wang X (2021) Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety. Frontiers in Oncology. 2021 Mar 25, 11:597453. doi: 10.3389/fonc.2021.597453(IF:5.738)
34.Jiang Y*, Lv X, Ge X, Qu H, Zhang Q, Lu K, Lu Y, Xue C, Zhang L, Wang X*. Wilms tumor gent 1 (WT1)-specific adoptive immunotherapy in hematologic diseases. International immunopharmacology. 2021 May; 94:107504. doi: 10.1016/j.intimp.2021.107504.(IF= 5.714)
35.Yujia Zhai, Xiangxiang Zhou*,Xin Wang*.Novel insights into the biomarkers and therapies of primary central nervous system lymphoma. Therapeutic Advances in Medical Oncology, 2022 May 4;14:17588359221093745.( IF=5.485)